Zoetis Inc - Class A

ZTS

$153.12

+31.88% (1 year change)

Avg closing price

Price range

Market Cap

$79.6 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$1.81 Billion

Total revenue in the last quarter.

Net Income

$359 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$3.42

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.65 (0.39%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

48.61x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$525 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

9,200

The number of full time employees.

Revenue & Earnings

Balance Sheet

Zoetis Inc - Class A

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.

News

Barclays Stick to Their Buy Rating for Zoetis By Investing.com

Barclays Stick to Their Buy Rating for Zoetis By Investing.com

Barclays Stick to Their Buy Rating for Zoetis

Investing.com Investing.com, 2 months ago
Zoetis Inc (ZTS) Q4 2020 Earnings Call Transcript

Zoetis Inc (ZTS) Q4 2020 Earnings Call Transcript

Zoetis Inc. (NYSE: ZTS) Q4 2020 earnings call dated Feb. 16, 2021. Operator Welcome to the Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast for Zoetis. […] The post Z...

AlphaStreet AlphaStreet, 2 months ago
Canine Arthritis Treatment Market Complete Analytical Report for 2029 with Key Players- Elanco, Zoetis, Bayer, VetStem Biopharma and Others

Canine Arthritis Treatment Market Complete Analytical Report for 2029 with Key Players- Elanco, Zoetis, Bayer, VetStem Biopharma and Others

A recent market study published by Future Market Insights (FMI) on the canine arthritis treatment including global industry analysis 2014-2018 & opportunity assessment 2019-2029, delivers a compreh...

OpenPR OpenPR, 2 months ago